Prophylactic NIV after planned extubation,
does it really help with Reduced reintubation within seven days versus high-flow nasal oxygen alone?
research showsThe grade is B. The 30-ICU French trial randomized 648 patients and obtained the primary outcome in 641. Seven-day reintubation was 40/339 (11.8%) with alternating NIV and high-flow oxygen versus 55/302 (18.2%) with high-flow oxygen alone, difference -6.4 points (95% CI -12.0 to -0.9). A two-ICU Spanish trial in very-high-risk patients also found 21/90 (23.3%) versus 35/90 (38.8%). Reintubation fell consistently, but populations and NIV strategies differed and the unmasked clinical decision remains a limitation, giving B with 72 points.
ads claimNIV is not an automatic home device for everyone after extubation. ICU teams must select high-risk patients and monitor airway protection, secretions, mask tolerance, gas exchange, and the danger of delayed reintubation.
Useful facts when choosing a product
- The large trial alternated NIV with high-flow nasal oxygen immediately after extubation.
- The second trial used 48 hours of actively humidified NIV in patients with at least four risk factors.
- Verdict 1541 addresses long-term home NIV after COPD exacerbation, not this ICU indication.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.prophylactic-noninvasive-ventilation-immediately-after-planned-extubation-in-high-risk-icu-patients.UNK.reintubation-within.reduce.UNKUnknown > Prophylactic noninvasive ventilation immediately after planned extubation in high-risk ICU patients > Unknown > reintubation within > Reduction claim > Unknown
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Thille randomized 648 participants; seven withdrew consent, leaving 641, 339 versus 302, in the primary outcome. We checked the seven-day reintubation outcome and comparator against NCT03121482; funding came from a French Ministry of Health research program. Hernández randomized 182, while primary events were reported in 90 participants per arm. NCT04125342 specified seven-day reintubation, and Fisher & Paykel supplied humidifiers and masks. Verdict 1541 concerns long-term home NIV after COPD exacerbation, a different indication from immediate prophylaxis after planned ICU extubation.
Why this is classified as B (72)
A large publicly funded trial and a separate smaller trial reduced actual reintubation, but population and intervention differences plus an unmasked clinical-decision endpoint give B with 72 points.
Counterpoint. B does not establish a mortality benefit. The supported claim is short-term reintubation reduction after planned extubation in selected high-risk patients.
Rejudgment record. Cross-check applied — We cross-checked the seven-day primary endpoint, randomized and analyzed counts, intervention composition, funding and device provision, and unmasked clinical reintubation decisions against both articles and registries.
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prophylactic NIV immediately after planned extubation reduces seven-day reintubation in high-risk patients. | B | The absolute difference was -6.4 points in the large trial and -15.5 points in the second. |
| Prophylactic NIV reduces ICU mortality. | D | The large trial's mortality interval included zero. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Thille AW et al. 2019 | Open-label multicenter randomized trial in 30 French ICUs | 648 randomized and 641 in the primary analysis, 339 versus 302 | French Ministry of Health Programme Hospitalier de Recherche Clinique National 2015 | Reintubation within seven days after planned extubation | 40/339 (11.8%) versus 55/302 (18.2%), difference -6.4 points (95% CI -12.0 to -0.9), P=.02 | Pivotal large publicly funded reintubation evidence |
| Hernández G et al. 2022 | Open-label randomized trial in two Spanish ICUs | 182 randomized; primary outcome reported in 180, 90 per arm | Fisher & Paykel Healthcare supplied humidifiers and masks and was reported to have no other study role | Reintubation within seven days after planned extubation | 21/90 (23.3%) versus 35/90 (38.8%), difference -15.5 points (95% CI -28.3 to -1.0) | Direct supporting evidence in a very-high-risk population |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-14).
Final verification and publication gate: Codex · Evidence date: 2026-08-14 · Corrections: none
Cite this verdict
[Chamgap] Prophylactic NIV after planned extubation x reintubation — Evidence Grade B·72. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/general/prophylactic-niv-planned-extubation-reintubation/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.